EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
…, K Chatzidionysiou, M Dougados, J Nam… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …
and consensual international recommendations on RA treatment are not available. In this …
Present and future of surface-enhanced Raman scattering
The discovery of the enhancement of Raman scattering by molecules adsorbed on nanostructured
metal surfaces is a landmark in the history of spectroscopic and analytical techniques. …
metal surfaces is a landmark in the history of spectroscopic and analytical techniques. …
Highly uniform and reproducible surface-enhanced Raman scattering from DNA-tailorable nanoparticles with 1-nm interior gap
… J. acknowledges support by the Public Welfare & Safety Research Program through NRF
funded … J. calculated the EFs. HK and SK carried out three-dimensional finite-element method …
funded … J. calculated the EFs. HK and SK carried out three-dimensional finite-element method …
Observation of Large Violation in the Neutral Meson System
…, E Nakano, M Nakao, H Nakazawa, JW Nam - Physical review …, 2001 - APS
We present a measurement of the standard model CP violation parameter sin 2 φ 1 based
on a 29.1 fb− 1 data sample collected at the ϒ (4 S) resonance with the Belle detector at the …
on a 29.1 fb− 1 data sample collected at the ϒ (4 S) resonance with the Belle detector at the …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
…, P Emery, C Gaujoux-Viala, L Gossec, J Nam… - Annals of the …, 2014 - ard.bmj.com
In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease-…
for the management of rheumatoid arthritis (RA) with synthetic and biological disease-…
[HTML][HTML] Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex
The Drosha-DGCR8 complex initiates microRNA maturation by precise cleavage of the stem
loops that are embedded in primary transcripts (pri-miRNAs). Here we propose a model for …
loops that are embedded in primary transcripts (pri-miRNAs). Here we propose a model for …
[PDF][PDF] Multimodal deep learning
… There are symmetric connections between the hidden and visible variables (Wi,j), but no
connections within hidden variables or visible variables. The model defines a probability …
connections within hidden variables or visible variables. The model defines a probability …
Use of normal tissue complication probability models in the clinic
…, LS Constine, A Eisbruch, SM Bentzen, J Nam… - International Journal of …, 2010 - Elsevier
The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes
the currently available three-dimensional dose/volume/outcome data to update and …
the currently available three-dimensional dose/volume/outcome data to update and …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, J Ledermann, S Williams, J Cosin, J Hoffman… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …